Core Viewpoint - The recent passing of 崔福斋, a key figure in 奥精医疗, is noted, but the company asserts that this will not affect its management stability or operational independence. However, the company is facing significant challenges due to a nationwide centralized procurement policy impacting its financial performance [6][9]. Company Overview - 奥精医疗, founded in 2004 by 崔福斋, is a leading enterprise in the field of artificial bone repair materials, focusing on the research, development, production, and sales of medical devices for tissue regeneration [8]. - The company achieved a market share of 13% in the artificial bone repair materials sector in 2020 [10]. Financial Performance - In 2024, 奥精医疗 is projected to experience a revenue decline of 9.03% and a net profit decrease of 123.35%, resulting in a loss of 12.66 million yuan [6][10]. - The primary reason for this decline is the implementation of centralized procurement for orthopedic artificial bones, which has led to a significant drop in product prices and increased operational costs [10][11]. Market Dynamics - The orthopedic bone repair materials market is currently dominated by allogeneic bone, which accounts for approximately two-thirds of the market. However, legal and ethical issues surrounding allogeneic bone may enhance the market share of artificial bone repair materials [10]. - The average price reduction for orthopedic medical consumables due to centralized procurement is reported to be 74%, which has adversely affected 奥精医疗's pricing and revenue [10]. Future Outlook - 奥精医疗 is expanding its business by acquiring HumanTech Dental in 2024, which will enhance its presence in the dental implant sector [11]. - The company is also increasing its sales personnel and marketing activities, which will lead to higher sales expenses and credit impairment losses [11].